Synthetic biology company Intrexon completes $150mm Series F round

In the same month in which it has signed infectious disease deals with AmpliPhi Biosciences and Soligenix, Intrexon Corp. (multigenic technologies that regulate biological molecules used in human drugs, protein production, industrial applications, agriculture biotech, and animal health) has also completed a $150mm Series F offering of preferred stock to 57 investors. Most of the funding came from first-time backers, which were joined by affiliates of Intrexon’s chairman and CEO Randal J. Kirk and Third Security. Including the current round of financing, Intrexon has raised a total of $509mm since inception. The company will use the new money to forge additional collaborations in the health care, food, energy, and environmental areas; further develop its platforms; and expand its sales and marketing and R&D teams.